IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9045457 B1

PDFFull Text
Date of Patent:
Jun. 02, 2015

Filed:

Oct. 03, 2013

Compositions and methods for treatment

Applicant:

Sarcode Bioscience Inc., Brisbane, CA (US);

Inventors:

Thomas Gadek, Oakland, CA (US);

John Burnier, Pacifica, CA (US);

Min Zhong, Foster City, CA (US);

Wang Shen, San Mateo, CA (US);

Johan D. Oslob, Sunnyvale, CA (US);

Kenneth Barr, Boston, MA (US);

Assignee:

SARcode Bioscience Inc., Bisbane, CA (US);

Attorney:

Troutman Sanders LLP

Primary Examiner:

Gigi Huang

Int. Cl.
CPC ...
C07D 217/00 (2006.01); C07D 405/06 (2006.01); A61K 31/198 (2006.01); A61K 31/404 (2006.01); A61K 31/4162 (2006.01); A61K 31/4184 (2006.01); A61K 31/4192 (2006.01); A61K 31/44 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/54 (2006.01); A61K 31/541 (2006.01); A61K 31/381 (2006.01); A61K 45/06 (2006.01); C07D 333/38 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); A61K 33/00 (2006.01); A61K 33/06 (2006.01); C07D 217/20 (2006.01); C07D 217/06 (2006.01);
U.S. Cl.
CPC ...
C07D 405/06 (2013.01); Y10S 514/914 (2013.01); C07D 217/00 (2013.01); A61K 31/198 (2013.01); A61K 31/404 (2013.01); A61K 31/4162 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/44 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 31/54 (2013.01); A61K 31/541 (2013.01); Y10S 514/912 (2013.01); A61K 31/381 (2013.01); A61K 45/06 (2013.01); C07D 333/38 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 471/04 (2013.01); A61K 33/00 (2013.01); A61K 33/06 (2013.01); C07D 217/20 (2013.01); C07D 217/06 (2013.01);
Abstract

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Find Patent Forward Citations

Loading…